Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia
- PMID: 12823076
- DOI: 10.4088/jcp.v64n0603
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia
Abstract
Background: Culture and ethnicity have been suggested to influence the presentation of patients with schizophrenia. These factors are thought to affect the diagnoses, courses of treatment, and medical utilization patterns of patients with schizophrenia. Specifically, the differences between whites, African Americans, and Mexican Americans are of particular importance, as these groups comprise the majority of the population in the United States today. The traditional course of treatment for many patients with schizophrenia is the drug haloperidol. However, research has shown that some ethnic groups (African Americans and Mexican Americans) may respond better to atypical drugs, such as olanzapine, but may be less likely to receive these drugs. A better response to the course of treatment results in improved medical utilization patterns. The purpose of this study was to examine if ethnicity helped predict whether Texas Medicaid patients were prescribed haloperidol versus olanzapine when other factors were controlled for.
Method: The study population consisted of 726 patients whose index drug was haloperidol and 1875 patients whose index drug was olanzapine. Patients had an ICD-9-CM diagnosis of schizophrenia or schizoaffective disorder. Texas medical and prescription claims data were used in a logistic regression analysis to determine significant predictors of the type of antipsychotic (haloperidol vs. olanzapine) patients were prescribed. Variables included in the analysis were ethnicity, gender, age, region, other mental illness comorbidities, and previous utilization of medications and resources. Data were collected from Jan. 1, 1996, to Aug. 31, 1998.
Results: The results show that when other demographic and utilization factors were controlled for, African Americans were less likely than whites to receive olanzapine rather than haloperidol.
Conclusion: Ethnicity is a significant predictor of the type of antipsychotic that is prescribed.
Similar articles
-
Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.Psychiatr Serv. 2004 Feb;55(2):151-6. doi: 10.1176/appi.ps.55.2.151. Psychiatr Serv. 2004. PMID: 14762239
-
Role of ethnicity in predicting antipsychotic medication adherence.Ann Pharmacother. 2003 May;37(5):625-30. doi: 10.1345/aph.1C321. Ann Pharmacother. 2003. PMID: 12708934
-
Racial disparity in the use of atypical antipsychotic medications among veterans.Am J Psychiatry. 2003 Oct;160(10):1817-22. doi: 10.1176/appi.ajp.160.10.1817. Am J Psychiatry. 2003. PMID: 14514496
-
Olanzapine: an updated review of its use in the management of schizophrenia.Drugs. 2001;61(1):111-61. doi: 10.2165/00003495-200161010-00011. Drugs. 2001. PMID: 11217867 Review.
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
Cited by
-
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC Psychiatry. 2010 Nov 3;10:89. doi: 10.1186/1471-244X-10-89. BMC Psychiatry. 2010. PMID: 21047395 Free PMC article.
-
Choice of atypical antipsychotic therapy for patients with schizophrenia: An analysis of a medicaid population.Curr Ther Res Clin Exp. 2005 Sep;66(5):463-74. doi: 10.1016/j.curtheres.2005.10.004. Curr Ther Res Clin Exp. 2005. PMID: 24790246 Free PMC article.
-
The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.Psychiatr Serv. 2012 Dec;63(12):1171-7. doi: 10.1176/appi.ps.201100408. Psychiatr Serv. 2012. PMID: 23026838 Free PMC article.
-
Agreement between self-reported and administrative race and ethnicity data among Medicaid enrollees in Minnesota.Health Serv Res. 2007 Dec;42(6 Pt 2):2373-88. doi: 10.1111/j.1475-6773.2007.00771.x. Health Serv Res. 2007. PMID: 17995548 Free PMC article.
-
Effects of Adherence to Pharmacological Treatment on the Recovery of Patients with Schizophrenia.Healthcare (Basel). 2021 Sep 18;9(9):1230. doi: 10.3390/healthcare9091230. Healthcare (Basel). 2021. PMID: 34575005 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical